Indacaterol maleate | ß2 adrenoceptor agonist/SRSF6 inhibitor
Available Options
| Size: | Price | Quantity | |
|---|---|---|---|
| 10 mg | $40.00 | ||
| 50 mg | $95.00 |
Indacaterol maleate (753498-25-8) is a full agonist (pEC50 = 8.06) of the human ß2 adrenoceptor.1,2 Clinically important drug for the treatment of chronic obstructive pulmonary disease. Indacaterol blocked colorectal cancer progression in vitro (IC50 = 19.01 µM) and in vivo via inhibition of the splicing factor SRSF6 by binding to its RRM2 domain.3 It also blocked cell migration in metastatic breast cancer MDA-MB-231 cells by a similar mechanism.4
References/Citations:
- Battram et al. (2006), In vitro and in vivo pharmacological characterization of 5-[(R)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quinolin-2-one (indacaterol), a novel inhaled ß2 adrenoceptor agonist with a 24-h duration of action; J. Pharmacol. Exp. Ther. 317 762
- Sturton et al. (2008), Pharmacological characterization of indacaterol, a novel once daily inhaled 2 adrenoceptor agonist on small airways in human and rat precision-cut lung slices; J. Pharmacol. Exp. Ther. 324 270
- Wan et al. (2017), SRSF6-regulated alternative splicing that promotes tumour progression offers a therapy target for colorectal cancer; Gut 68 118
- Ayama-Canden et al. (2023), Indacaterol inhibits collective cell migration and IGDQ-mediated single cell migration in metastatic breast cancer MDA-MB-231 cells; Cell Commun. Signal. 21 301
C24H28N2O3·C4H4O4
>98% HPLC
NMR: (Conforms)
Safety Data Sheet:
Product Data Sheet:
Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications. Please note that we do not sell to individuals and that all orders placed by non-research organizations will incur a $20 restocking/refund fee
Indacaterol maleate (753498-25-8) is a full agonist (pEC50 = 8.06) of the human ß2 adrenoceptor.1,2 Clinically important drug for the treatment of chronic obstructive pulmonary disease. Indacaterol blocked colorectal cancer progression in vitro (IC50 = 19.01 µM) and in vivo via inhibition of the splicing factor SRSF6 by binding to its RRM2 domain.3 It also blocked cell migration in metastatic breast cancer MDA-MB-231 cells by a similar mechanism.4
References/Citations:
- Battram et al. (2006), In vitro and in vivo pharmacological characterization of 5-[(R)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quinolin-2-one (indacaterol), a novel inhaled ß2 adrenoceptor agonist with a 24-h duration of action; J. Pharmacol. Exp. Ther. 317 762
- Sturton et al. (2008), Pharmacological characterization of indacaterol, a novel once daily inhaled 2 adrenoceptor agonist on small airways in human and rat precision-cut lung slices; J. Pharmacol. Exp. Ther. 324 270
- Wan et al. (2017), SRSF6-regulated alternative splicing that promotes tumour progression offers a therapy target for colorectal cancer; Gut 68 118
- Ayama-Canden et al. (2023), Indacaterol inhibits collective cell migration and IGDQ-mediated single cell migration in metastatic breast cancer MDA-MB-231 cells; Cell Commun. Signal. 21 301
Calculate the molar concentration, mass or volume in a solution.
Concentration × Volume × Molecular Weight = Mass
Focus Biomolecules • Plymouth Meeting, PA USA • 1-855-FOCUS21
Focus Biomolecules
Plymouth Meeting, PA USA
1-855-FOCUS21
Website Created by Advanta Advertising LLC.